Joseph E. Payne, President & CEO, Director of the BoardJoseph E. Payne, is President and Chief Executive Officer of Arcturus Therapeutics Ltd. He has served on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Pad Chivukula, CSO & COO, Director of the BoardDr. Chivukula serves as Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics Ltd. He has served on Arcturus’s Board since March 2013. Prior to Arcturus, from June 2008 until February 2013, Dr. Chivukula was employed by Nitto Denko Corporation, where his titles included Group Leader and Chief Scientist, and where he led the polymeric RNAi research department. Dr. Chivukula's background includes over 15 years of experience in drug delivery and therapeutic drug development at Nitto Denko Corporation and the University of Utah. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in lipid-mediated delivery systems and technology.
Craig Willett, Director of the BoardMr. Willett has served on Arcturus Therapeutics Ltd. Board since March 2013. He is the President and CEO of Voice of the Entrepreneur, Inc. providing start up coaching services to the next generation of entrepreneurs. He is the past President and CEO of UTAZ Development Corporation, the innovator of "Own For Less Than Rent" office space. Craig has demonstrated his ability to assemble capital and lead development teams to extraordinary success as reflected in the success of the nearly $700 million of projects to which he has offered his vision and leadership. He is also a real estate broker and CPA and holds bachelor's and master's degrees in accounting from Brigham Young University. As the founder of an accounting firm specializing in business and real estate tax issues he is a recognized business and tax authority testifying in both houses of Congress and has been quoted in the New York Times, the Washington Post, and the Wall Street Journal. Craig was also a founding director of Capital Community Bank. He is a Founder in the Brigham Young University Center for Entrepreneurship. He has served on many community development boards most recently Banner Children's Hospital Capital Campaign Board.
Stuart Collinson, Executive Chairman of the BoardDr. Collinson has served on Arcturus Therapeutics Ltd. Board since May 2014 and has served as Executive Chairman since January 2015. He is a partner at Forward Ventures and also the Executive Chairman of Tioga Pharmaceuticals, Inc. Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences Corp. (acquired by Vertex Pharmaceuticals Inc.). Before Aurora, Dr. Collinson was Chief Executive Officer of Andaris Limited (acquired by Quadrant, now part of Perrigo). He held senior management positions at GlaxoWellcome plc (now GlaxoSmithKline plc) and Baxter International Inc., and was a consultant with The Boston Consulting Group. Dr. Collinson was previously a director of Affinium Pharmaceuticals, Inc. (acquired by Debiopharma Group), Cabrellis Pharmaceuticals Corp. (acquired by Pharmion Corp., now part of Celgene Corp.), Conforma Therapeutics Corp. (acquired by BiogenIdec, Inc.), GeneOhm Sciences, Inc. (acquired by Becton, Dickinson and Company), NovaCardia, Inc. (acquired by Merck & Co, Inc.), and Proprius Pharmaceuticals, Inc. (acquired by Cypress Bioscience, Inc.), and Vertex Pharmaceuticals Inc. Dr. Collinson received an M.B.A. from Harvard Business School and a Ph.D. in Physical Chemistry from the University of Oxford.
Daniel Geffken, Director of the BoardPrior to joining the Arcturus Therapeutics Ltd. Board in November 2017, Mr. Geffken had served on the Alcobra Board since their initial public offering in May 2013. Since October 2011, he has been Managing Director of Danforth Advisors, LLC, a management consulting firm that provides financial and strategic support to emerging life science companies. Mr. Geffken has also been Chief Financial Officer or Chief Operating Officer of eight companies, four of which were U.S. public reporting companies and six of which were life science companies. He has a B.S. in Economics from The Wharton School, University of Pennsylvania, and a M.B.A. from Harvard Business School.
David Shapiro, Director of the BoardDr. Shapiro joined the Arcturus Therapeutics Ltd. Board in November 2017 and currently serves as Chief Medical Officer and Executive Vice President of development at Intercept Pharmaceuticals, Inc., a public pharmaceutical company, a position he has held since 2008. He has over 25 years of clinical development experience in the pharmaceutical industry. Dr. Shapiro founded a consulting company, Integrated Quality Resources, that focused on development stage biopharmaceutical companies and was active in this role from 2005 to 2008. From 2000 to 2005, Dr. Shapiro was Executive Vice President, medical affairs and Chief Medical Officer of Idun Pharmaceuticals, Inc., prior to its acquisition by Pfizer Inc. From 1995 to 1998, he was President of the Scripps Medical Research Center at Scripps Clinic. He also served as Vice President, clinical research at Gensia Pharmaceuticals, Inc. and as Director and Group Leader, hypertension clinical research at Merck Research Laboratories from 1985 to 1990. Dr. Shapiro has authored more than 20 peer-reviewed publications and organized and chaired several conferences aimed at improving product development. Dr. Shapiro served on the board of directors of Altair Therapeutics, Inc. from 2008 to 2010 and served for two terms on the Executive Committee of the Board of the American Academy of Pharmaceutical Physicians, from 1997 to 2000 and from 2004 to 2005. He is an elected Fellow of both the Royal College of Physicians of London and the Faculty of Pharmaceutical Physicians of the United Kingdom. He received his medical degree from Dundee University & Medical School, and undertook his postgraduate medical training in the university affiliated hospitals in Oxford, United Kingdom and the University of Vermont.
Orli Tori, Director of the BoardPrior to joining the Arcturus Therapeutics Ltd. Board in November 2017, Orli Tori had served on the Alcobra Board since August 2016. Ms. Tori is an experienced executive with over 20 years of practice in leading teams towards their goals and beyond. Since 2012 and until recently, Ms. Tori served as Chief Executive Officer of BIRAD Ltd., managing Bar Ilan University's IP and commercialization efforts as well as all research collaborations with Industry. During her tenure, the company built a diverse portfolio of companies based on University IP. Before joining BIRAD, Ms. Tori spent 20 years in the pharmaceutical industry, fulfilling different positions including, General Manager of Neopharm Israel Ltd. from 2007 through 2012, ($200 Million revenues), and SVP Corporate BD of the Neopharm Group, and was responsible for the group overall corporate development activities, including structuring, negotiating and closing transactions. Ms. Tori is former chairperson of the Israeli Technology Transfer Organization. Ms. Tori obtained her M.Sc. in Microbiology (cum laude) and B.Sc. in Life Sciences at Tel Aviv University in Tel Aviv, Israel, and graduated the Executive Program for senior business managers at the Tel Aviv University School of Business.
Craig is the President and CEO of Voice of the Entrepreneur, Inc. providing start up coaching services to the next generation of entrepreneurs.
Dr. Stuart Collinson is a partner at Forward Ventures and also the Executive Chairman of Tioga Pharmaceuticals, Inc.
January 7, 2018
Arcturus Therapeutics to Present in a Panel Discussion at East/West CEO Conference Called “Challenges and Opportunities in Biotech” on Sunday, Jan 7th 2018, from 11:20 am - 11:50 am.
January 5, 2018
Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients' Lives
January 4, 2018
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics